CoChat
Sign Up
Cited by 412Systemic Lupus Erythematosus ResearchSystemic Sclerosis and Related DiseasesVenous Thromboembolism Diagnosis and Management

The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.

Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus

Ruiz-Irastorza, G, Egurbide, M-V, Pijoan, J-I, Garmendia, M, Villar, I, Martinez-Berriotxoa, A, Erdozain, J-G, Aguirre, C·2006·Lupus
DOI 10.1177/0961203306071872
Open this paper in CoChat — free account

Abstract

Antimalarials have shown beneficial effects on systemic lupus erythematosus (SLE) activity. Our aim was to investigate whether antimalarials protect against thrombosis and influence survival in SLE patients. A prospective cohort including 232 patients with SLE were included in the study at the time of lupus diagnosis. End points were documented thrombosis and death due to any cause. A Cox regression-multiple-failure time survival analysis model was fitted to establish the effect of antimalarials on the development of thrombosis. Kaplan-Meier survival curves and propensity score adjusted-Cox regression analysis were performed to investigate the effect of antimalarials use on survival. Of our subjects, 204 patients (88%) were women. 230 patients (99%) were white. 150 patients (64%) had ever received antimalarials. Median time on antimalarials was 52 months (range three to 228 months). The Cox multiple-failure time survival analysis showed that taking antimalarials was protective against thrombosis (HR 0.28, 95%CI 0.08-0.90), while aPL-positivity (HR 3.16, 95%CI 1.45-6.88) and previous thrombosis (HR 3.85, 95%CI 1.50-9.91) increased the risk of thrombotic events. Twenty-three patients died, 19 of whom (83%) had never received antimalarials. No patient treated with antimalarials died of cardiovascular complications. Cumulative 15-year survival rates were 0.68 for never versus 0.95 for ever treated patients ( P < 0.001). Age at diagnosis and propensity score-adjusted HR for antimalarials ever versus never users was 0.14 (95%CI 0.04-0.48). Our study shows a protective effect of antimalarials against thrombosis and an increased survival of SLE patients taking these drugs. These data support the routine use of antimalarials in all patients with SLE.

Overview

Integrity signals

Registry

Crossref · 10.1177/0961203306071872

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 48 references

Research works printed but not linked: 3

  1. Rosembaum PR , Rubin DB. The central role of propensity scores in estimating dose-response functions . Biometrika 1983; 70: 41-55 .
  2. 10.1177/0961203396005001031 · DOI · Paper page
  3. Alarcón GS , McGwin G, Jr. , Fessler BJ et al. “Confounding by indications” partially explains the protective effect of hydroxychloroquine (HCQ) in SLE survival: Data from a multiethnic US cohort . Arthritis Rheum 2005; 52: S726-S726 .

Cited by

Sorted by citations

Items 201–300 of 412

Related

See all

Metadata

Authors
Ruiz-Irastorza, G., Egurbide, M.-V., Pijoan, J.-I., Garmendia, M., Villar, I., Martinez-Berriotxoa, A., Erdozain, J.-G., & Aguirre, C.
Affiliations
  • Department of Internal Medicine, Hospital de Cruces, University of the Basque Country, Bizkaia, Spain,
  • University of the Basque Country (ES)
  • Department of Internal Medicine, Hospital de Cruces, University of the Basque Country, Bizkaia, Spain
ORCID
Venue
Lupus
Publisher
SAGE Publications
Published
2006-09
Volume
15
Issue
9
Pages
577-583
ISSN
  • 0961-2033 (ISSN-L)
  • 1477-0962
DOI
10.1177/0961203306071872
OpenAlex
W2014873778
Cited by
411
References
48
Citations by year
2026: 11 · 2025: 7 · 2024: 30 · 2023: 24 · 2022: 19 · 2021: 22 · 2020: 29 · 2019: 23 · 2018: 27 · 2017: 17 · 2016: 18 · 2015: 20 · 2014: 28 · 2013: 22 · 2012: 25
FWCI
11.16
Type
journal article
Language
en
Open access
closed
Licence
journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations
  • Lupus (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
  • Health Sciences › Medicine › Rheumatology › Systemic Sclerosis and Related Diseases
  • Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
Keywords
antimalarial drugs, systemic lupus erythematosus, thrombosis, survival, antiphospholipid antibodies, cardiovascular complications, mortality, hydroxychloroquine, chloroquine
MeSH terms
Adult, Analysis of Variance, Antimalarials, Cause of Death, Female, Follow-Up Studies, Humans, Lupus Erythematosus, Systemic, Male, Middle Aged, Prospective Studies, Research Design, Risk Factors, Spain, Thrombosis, Time Factors, Survival Rate, Proportional Hazards Models, Survival Analysis, Treatment Failure, Endpoint Determination

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review